Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Pathology

Show all topics

DOI

10.1016/s1470-2045(17)30469-2

License

publisher-specific-oa